Accelerated second-line or maintenance chemotherapy versus treatment at disease progression in NSCLC. - Wikidata - awgldk - TriplyDB

Accelerated second-line or maintenance chemotherapy versus treatment at disease progression in NSCLC.

Accelerated second-line or maintenance chemotherapy versus treatment at disease progression in NSCLC.

http://www.wikidata.org/entity/Q37732287

about

Accelerated second-line or maintenance chemotherapy versus treatment at disease progression in NSCLC.

http://www.wikidata.org/entity/Q37732287

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on April 2010

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Accelerated second-line or mai ...... disease progression in NSCLC.

@en

Accelerated second-line or mai ...... disease progression in NSCLC.

@nl

type

label

Accelerated second-line or mai ...... disease progression in NSCLC.

@en

Accelerated second-line or mai ...... disease progression in NSCLC.

@nl

prefLabel

Accelerated second-line or mai ...... disease progression in NSCLC.

@en

Accelerated second-line or mai ...... disease progression in NSCLC.

@nl

P1433

Q37732287-5334F691-4C92-4550-AE19-4E592767A335

P1476

Q37732287-9605B5A7-95DE-4AB4-90DD-4A8DCD97BFF9

P2093

Q37732287-167F3551-6907-4BCC-ABA2-5E483EDD7D4B

Q37732287-298174D5-5F51-4E6A-8938-3524D0CE0495

Q37732287-7311F198-6FCF-40F4-AC8C-1CDC1835A497

Q37732287-9A5CEAFD-A9C9-4658-B4D3-0C9A792B780D

Q37732287-C807E128-48D9-44D6-AC55-FB6D3633FD04

Q37732287-E52C067B-4836-433F-B34C-9B8DD671E847

P2860

Q37732287-0CDDEEF3-71F0-4C9E-B627-EE45D19D089C

Q37732287-121BBE45-56BE-42FB-B4D4-100C7DDD2A1E

Q37732287-12AF31B1-4302-4AA8-8F71-4D5CB390D308

Q37732287-177503FA-66E9-4F7D-B0B9-35ACBDC30526

Q37732287-1C8B072E-C6D9-495E-8EE9-B04A91814C79

Q37732287-49FDB5B5-9527-4EFB-B5B6-B9A993B8D86D

Q37732287-4ED340CD-4AE7-4E1F-B2E0-C544A3AAD858

Q37732287-681C02A7-45A5-4669-A192-4AC16F0FD264

Q37732287-71EB0ACE-3696-4001-BC18-46B2584FD88C

Q37732287-78024A7B-1E61-4188-81F2-DAB55B967857

P304

Q37732287-7624F5D5-F199-45B1-B6CB-BFC1688F8A11

P31

Q37732287-E9689BB4-0424-447C-AED7-7123A03E7B72

P356

Q37732287-9B3570B5-C1CF-457B-8D42-4F0FA390CE2E

P433

Q37732287-E7E085EA-2F4F-4D2A-B033-BBF5C00B6822

P478

Q37732287-3084A6F1-D048-4A7E-ABD4-371B9A361624

P577

Q37732287-9E46219B-0AA9-4C96-B989-D79B22091741

P698

Q37732287-C828E23E-0426-48B8-AA8F-4F0897D4127F

P921

Q37732287-0FAFCFD8-E261-4009-9E6B-98D391239274

P356

P1433

Expert Review of Anticancer Therapy

P1476

Accelerated second-line or mai ...... disease progression in NSCLC.

@en

P2093

Astrid Belalcazar

http://www.w3.org/2001/XMLSchema#string

Edgardo S Santos

http://www.w3.org/2001/XMLSchema#string

Gelenis Domingo

http://www.w3.org/2001/XMLSchema#string

Luis E Raez

http://www.w3.org/2001/XMLSchema#string

Marcelo Blaya

http://www.w3.org/2001/XMLSchema#string

Michel Velez

http://www.w3.org/2001/XMLSchema#string

P2860

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

Erlotinib in previously treated non-small-cell lung cancer

Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer

Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer

Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer.

Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group.

Comparison of docetaxel and docetaxel-irinotecan combination as second-line chemotherapy in advanced non-small-cell lung cancer: a randomized phase II trial.

Phase III study of second-line chemotherapy for advanced non-small-cell lung cancer with weekly compared with 3-weekly docetaxel.

Phase III study comparing oral topotecan to intravenous docetaxel in patients with pretreated advanced non-small-cell lung cancer.

P304

549-557

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1586/ERA.10.30

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

10

http://www.w3.org/2001/XMLSchema#string

P577

2010-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20397920

http://www.w3.org/2001/XMLSchema#string

P921